Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladarixin and Sotorasib in Advanced KRAS G12C Mutant NSCLC
NCT05815173Phase 1Recruiting
- Sponsor
- NYU Langone Health
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ladarixin in non-small cell lung cancer (NSCLC), sponsored by NYU Langone Health. Primary endpoints: Dose-Limiting Toxicities at Day 21 and Progression-Free Survival at Month 36. Started Aug 2023; status: recruiting.
02
Drugs
ladarixin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05815173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815173.